Table of Contents
<< Previous Issue | Dec 2023 (Vol: 2023, Issue: 12) | Next Issue >> |
- Section: Licensing
-
Merck KGaA Signs Licensing Agreement with Abbisko for Pimicotinib
- Section: Mergers & Acquisitions
-
AbbVie to Acquire ImmunoGen for US$10.1 B
-
AbbVie to Buy Cerevel Therapeutics for US$8.7 B to Bolster Neuroscience Portfolio
-
Roche to Acquire Carmot Therapeutics for US$3.1 B
- Section: Research & Development
-
Bristol Myers Squibb Signs Licensing Deal with Avidity Biosciences for Multiple Cardiovascular Targets